



# CHEMOTHERAPY ORDERS

BRINK, LINDA  
6/11/53

Patient Label

TO BE COMPLETED BY PHYSICIAN:

Patient Name:

DOB:

Date Written: 2/10/20

Date of Administration: 2/12/20

Diagnosis: Lung Ca (small cell)

TNM Stage: Limited stage

Protocol / Regimen -  
Cisplatin / VP16

Cycle 1 of 4  
Day 2 + 3

Allergies: ☒ NKDA

Venous Access: ☐ Peripheral ☐ Central

Height

5 ft 3 in

Weight

140 lb

☒ Actual

☐ Ideal

☐ Adjusted

☒ Dosing

Body Surface  
Area (m<sup>2</sup>)

1.65

Emetic Level

☐ Minimal

☐ Moderate

☒ High

Repeat entire  
order in 2 days  
(Day 1 at  
Cystine Ren)

Lab Orders:

CBC/DIFF

BMP

Magnesium

UA

Hold Parameters:

ANC less than:

WBC less than:

PLT less than:

Hgb/Hct less than:

SCr greater than:

Non-chemotherapy orders:

RPh initials / Nurse initials

☐ IV Fluids: NS @ KVO (20 mL/hr)

# 20 FRAM 16g IV

Dexamethasone 12g IV

IV NS @ 20cc at 500 cc/10 x 2 hours

Pre chemo with Lasix 20g IV

IV NS @ 20cc at 500 cc/10 x 2 hours

Post chemo with Lasix 20g IV

Solution, volume and infusion rate are per manufacturer/hospital guidelines unless otherwise specified. Chemotherapeutic agents will be rounded down to nearest vial size if within 5% of calculated dose. Biological agents will be rounded down to the nearest vial size if within 10% of calculated dose. Please administer chemotherapy in sequence listed below.

Chemotherapy	Dose per Unit (m <sup>2</sup> , kg, AUC)	Dose Reduction* (mg/m <sup>2</sup> , mg/kg, AUC)	Calculated Dose	Dose Dispensed (Rounding to be completed by RPh)	Route	Infusion Rate	RPh / Nurse initials
Cisplatin	25g/m <sup>2</sup>		42g	with 12.5g marmetol			
				250 cc NS over 30 minutes			
VP16	100g/m <sup>2</sup>		168g	16g in 500 cc NS over 90 minutes			

\*If using a dose reduction, please provide rationale:

MD Name (Print) Manuel Perera MD Signature

Date/Time 2/10/20

RN Name (Print) RN Signature

Date/Time

RPh Name (Print) RPh Signature

Date/Time



155 Crystal Run Road  
Middletown, NY 10941

845-703-6999  
www.crystalrunhealthcare.com

Patient: Linda Brink  
Date of Birth: 06/11/1953  
Date: 02/07/2020 11:15 AM  
Encounter Type: Office Visit

This 66 year old female presents for Small cell lung cancer.

#### History of Present Illness:

1. Small cell lung cancer

No nausea or vomiting, No fever chills or sweats. Eating well, No pain, Mild SOB on oxygen.

#### PROBLEM LIST: Problem List reviewed.

Problem Description	Onset Date	Chronic	Clinical Status	Notes
Small cell lung cancer		Y		

#### Allergies:

Ingredient	Reaction (Severity)	Medication Name	Comment
NO KNOWN ALLERGIES			
NO KNOWN ALLERGIES			

Reviewed, no changes.

#### Review of Systems

System	Neg/Pos	Details
Constitutional	Positive	Fatigue.
Constitutional	Negative	Fever and Night sweats.
ENMT	Negative	Nasal drainage.
Eyes	Negative	Vision changes.
Respiratory	Positive	Dyspnea.
Respiratory	Negative	Cough.
Cardio	Negative	Claudication and Irregular heartbeat/palpitations.
GI	Negative	Abdominal pain, Constipation, Decreased appetite, Diarrhea and

Brink, Linda 000000751627 06/11/1953 02/07/2020 11:15 AM 1/4

GU	Negative	Vomiting.
Endocrine	Negative	Dysuria and Hematuria.
Neuro	Negative	Cold intolerance and Heat intolerance.
Integumentary	Negative	Gait disturbance and Headache.
MS	Negative	Pruritus and Rash.
Hema/Lymph	Negative	Back pain.
Allergic/Immuno	Negative	Easy bleeding and Easy bruising.
		Environmental allergies and Food allergies.

**PAST MEDICAL/SURGICAL HISTORY (Detailed)**

Disease/disorder	Onset Date	Management	Date	Comments
COPD				
Hypertension				

**Family History (Detailed)**

Relationship	Family Member Name	Deceased	Age at Death	Condition	Onset Age	Cause of Death
Father				Cancer, lung		N
Paternal grandmother				Cancer, lung		N

**Social History: (Reviewed, updated)**

Tobacco use reviewed.

Preferred language is English.

Smoking status: Former smoker.

**SMOKING STATUS**

Type	Smoking Status	Usage Per Day	Years Used	Total Pack Years
	Former smoker			

**Medications (active prior to today)**

Medication Name	Sig Description	Start Date	Stop Date	Refilled	Rx Elsewhere
amlodipine 5 mg tablet	take 1 tablet by oral route every day	//			Y
Primlev 5 mg-300 mg tablet	take 1 tablet by oral route every 6 hours as needed for pain	//			Y
magnesium 400 mg (as magnesium oxide) capsule	wash 1 capsule by oral route every day for 30 hours	//			Y
Anoro Ellipta 62.5 mcg-25 mcg/actuation powder for inhalation	inhale 1 puff by inhalation route every day at the same time each day	//			Y
Mucinex 600 mg tablet, extended release	take 1 tablet by oral route every 12 hours as needed	//			Y

**Medication Reconciliation**

Medications reconciled today.

## Vital Signs

Time	BP	Pulse	Resp	Temp F	Ht ft	Ht in	Ht cm	Wt lb	Wt kg	BMI	BSA m2	O2
	mm/Hg	/min	/min							kg/m2		Sat%
11:41 AM	94/50	114		97.1	5.0	3.00	160.02	140.50	63.730	24.89		96

## Measured By

Time	Measured by
11:41 AM	Cynthia Morris

## Physical Exam:

Exam	Findings	Details
Constitutional	Normal	Well developed.
Eyes	Normal	Conjunctiva - Right: Normal, Left: Normal.
Ears	Normal	Inspection - Right: Normal, Left: Normal.
Nasopharynx	Normal	External nose - Normal, Lips/teeth/gums - Normal. Tonsils - Normal. Oropharynx - Normal.
Neck Exam	Normal	Inspection - Normal. Palpation - Normal.
Lymph Detail	Normal	No cervical or supraclavicular adenopathy.
Respiratory	Normal	Inspection - Normal. Auscultation - Normal. Effort - Normal.
Cardiovascular	Normal	Regular rate and rhythm. No murmurs, gallops, or rubs.
Abdomen	Normal	Inspection - Normal. Auscultation - Normal. No abdominal tenderness. No hepatic enlargement. No splenic enlargement.
Skin	Normal	Inspection - Normal.
Musculoskeletal	Normal	Visual overview of all four extremities is normal.
Extremity	Normal	No edema.
Psychiatric	Normal	Orientation - Oriented to time, place, person & situation. Appropriate mood and affect. Normal insight. Normal judgment.

The patient's functional status score is at 1 and is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work

## Assessment/Plan

#	Detail Type	Description
1.	Assessment	Small cell lung cancer (C34.90).
	Provider Plan	The pt has biopsy proven small cell lung cancer. MRI brain is negative. PET scan reviewed. The pt has extensive mediastinal disease with extension into the left lingula and RUL. There is no evidence for metastatic disease. It is unclear if the entire volume of disease can be encompassed in 1 radiation field however I have advised consultation with rad onc. If nothing else, the bulk of disease could be covered. Will administer concurrent cisplatin 25 mg/m2 /VP 16 100 mg/m2 D1-3 every 3 weeks for 4 cycles. Side effects include, but are not limited to nausea, vomiting, diarrhea, mucositis, alopecia, malaise, cytopenias, renal failure, hearing loss, neuropathy and unexpected side effects. Questions answered. Full informed consent obtained. The goal of rx is cure however the pt understands that she is very high risk and that recurrence is likely. XRT consulted. Chemotherapy authorization requested. Antiemetics sent. Teaching scheduled. OV next week.
2.	Assessment	Normochromic normocytic anemia (D64.9).
	Provider Plan	Stable
3.	Assessment	Chronic obstructive pulmonary disease, unspecified COPD type (J44.9).

Provider Plan Oxygen dependent

**Medications (added, continued, or stopped today):**

Started	Medication	Directions	Instruction	Stopped
	amlodipine 5 mg tablet	take 1 tablet by oral route every day		
	Anoro Ellipta 62.5 mcg-25 mcg/actuation powder for inhalation	inhale 1 puff by inhalation route every day at the same time each day		
	magnesium 400 mg (as magnesium oxide) capsule	wash 1 capsule by oral route every day for 30 hours		
	Mucinex 600 mg tablet, extended release	take 1 tablet by oral route every 12 hours as needed		
	Primlev 5 mg-300 mg tablet	take 1 tablet by oral route every 6 hours as needed for pain		
02/07/2020	Zofran 8 mg tablet	take 1 tablet by ORAL route every 8 hours for 3 days and as needed for nausea		02/09/2020

**Counseling / Educational Factors:**

Counseling / educational factors reviewed.

**Provider:**

Perry MD, Manuel 02/07/2020 2:53 PM

Document generated by: Manuel Perry MD 02/07/2020 02:53 PM

Crystal Run Healthcare, LLP

Electronically signed by Manuel Perry MD on 02/07/2020 03:29 PM

Crystal Run Healthcare Physicians LLP

Brink, Linda  
609 Avenue N  
Matamoras, PA, 18336  
Person #: 1033055  
Sex: F  
DOB: 06/11/1953

Order Date: 02/04/2020

Ordering: Perry MD, Manuel

Location: Middletown 155

Tests Ordered : Retic Count (RETICX), CBC With Auto Diff (CBCA), Complete Metabolic Profile (CMP) (CMP), LD (Lactate D ehydrogenase) (LDH), Iron+TIBC (IRIBC), Ferritin (FERR), Folate (FOL), Vitamin B12 (VB12), CBCA XT (CBCA XT)

Iron+TIBC (Collection Date: 02/04/2020 09:54, Status: Final)

Component	Result	Units	Flag	Range	Comment
% SAT	7	%	L	15-50	
Iron	14	ug/dL	L	27-170	
TIBC	193	ug/dL	L	250-450	

LDH (Collection Date: 02/04/2020 09:54, Status: Final)

Component	Result	Units	Flag	Range	Comment
LDH	188	U/L		110-250	

Vitamin B12 (Collection Date: 02/04/2020 09:54, Status: Final)

Component	Result	Units	Flag	Range	Comment
VIT B12	358	pg/mL		180-914	

Folate (Collection Date: 02/04/2020 09:54, Status: Final)

Component	Result	Units	Flag	Range	Comment
Folate	11.1	ng/mL		5.9-24.8	

Ferritin (Collection Date: 02/04/2020 09:54, Status: Final)

Component	Result	Units	Flag	Range	Comment
Ferritin	792	ng/mL	H	11-264	

Retic Count (Collection Date: 02/04/2020 09:54, Status: Final)

Component	Result	Units	Flag	Range	Comment
XT RET#	0.075	m/uL		0.010-0.080	
XT RET%	2.0	%	H	0.5-1.5	

CMP (Collection Date: 02/04/2020 09:54, Status: Final)

Component	Result	Units	Range	Comment
-----------	--------	-------	-------	---------

Patient: Brink, Linda , DOB: 06/11/1953

			<u>Fl</u> <u>a</u> <u>g</u>
Albumin	3.2	g/dL	L 3.5-5.0
ALP	104	U/L	28-109
ALT	29	U/L	3-60
AST	22	U/L	4-60
BUN	13	mg/dL	7-30
Calcium	9.0	mg/dL	8.5-10.4
Chloride	101	mmol/L	98-109
CO2	28	mmol/L	22-30
Creatinine	0.5	mg/dL	0.5-1.1
eGFR	123.2	mL/min/1.73m2	>=60.0 eGFR NON AFRICAN AMERICAN

eGFRAA 149.3 ML/MIN/1.73m2 >=60.0 eGFR AFRICAN AMERICAN

Glucose	117	mg/dL	H 65-105
Potassium	4.0	mmol/L	3.5-5.2
Sodium	139	mmol/L	136-145
Total Bili	0.5	mg/dL	<1.3
Total Protein	7.1	g/dL	6.2-8.2

**CBCA XT (Collection Date: 02/04/2020 09:54, Status: Final)**

<u>Component</u>	<u>Result</u>	<u>Units</u>	<u>Flag</u>	<u>Range</u>	<u>Comment</u>
NRBC#	0.00	K/uL			
NRBC%	0.0	%			
XT Baso#	0.02	K/uL		0.00-0.20	
XT Baso%	0.1	%		0.0-1.5	
XT Eo#	0.19	K/uL		0.00-1.10	
XT Eo%	1.0	%		1.0-10.0	
XT HCT	32.5	%	L	35.0-47.0	
XT HGB	9.9	g/dL	L	11.7-15.7	
XT IG#	0.14	K/uL	H	<=0.10	
XT IG%	0.7	%		<=1.0	
XT Lymph#	0.56	K/uL	L	0.60-4.00	
XT Lymph%	2.9	%	L	15.0-45.0	
XT MCH	25.8	pg	L	26.0-33.0	
XT MCHC	30.5	g/dL	L	32.0-36.0	
XT MCV	84.6	fL		80.0-97.0	
XT Mono#	1.8	K/uL	H	0.1-1.2	
XT Mono%	9.4	%	H	1.5-9.0	
XT MPV	9.9	fL		7.0-11.0	
XT Neut#	16.7	K/uL	H	1.5-8.1	
XT Neut%	86.6	%	H	41.0-74.0	
XT PLT	492	K/uL	H	140-440	

Patient: Brink, Linda, DOB: 06/11/1953

XT RBC	3.84	m/uL	3.80-5.20
XT WBC	19.2	K/uL H	3.5-11.0